key: cord-0818585-15tr614l
authors: Masi, Paul; Hékimian, Guillaume; Lejeune, Manon; Chommeloux, Juliette; Desnos, Cyrielle; Pineton De Chambrun, Marc; Martin-Toutain, Isabelle; Nieszkowska, Ania; Lebreton, Guillaume; Bréchot, Nicolas; Schmidt, Matthieu; Edouard Luyt, Charles; Combes, Alain; Frere, Corinne
title: Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19–Associated Coagulopathy: Insights From a Prospective, Single-Center Cohort Study
date: 2020-06-17
journal: Circulation
DOI: 10.1161/circulationaha.120.048925
sha: 1ce049f61dec467a26e614192602b5875a4c317b
doc_id: 818585
cord_uid: 15tr614l

nan

We observed that unlike non-COVID-19 ARDS, COVID-19 ARDS was associated with a significant increase in procoagulants, which closely correlates with the elevation of acute phase reactants. This led to a pronounced imbalance between procoagulants and anticoagulants and uncontrolled thrombin generation. Endothelial dysfunction, reflected by von Willebrand factor release, and hypoxia-mediated hypercoagulability also participate in the procoagulant state 1,4 but are nonspecific because they were observed in all patients with ARDS. In patients with COVID-19, tissue plasminogen activator and PAI-1 correlated with lactate dehydrogenase, suggesting a potential role of pulmonary endothelial cell dysfunction in the local regulation of coagulation/fibrinolysis balance and in situ pulmonary thrombosis. We did not observe any fibrinolysis shutdown. A role for antiphospholipid antibodies in COVID-19-associated coagulopathy has been suggested, but we observed a high frequency of antiphospholipid antibodies in all patients with ARDS.

We acknowledge that this study has several limitations, including its small sample size, its single-center design, the use of a single time point for biomarkers evaluation, and comparison between two groups of patients with ARDS who may have different clinical courses. Therefore, our results cannot be generalized to all patients with COVID-19.

In conclusion, our findings suggest that the systemic inflammatory response is a major contributor to COVID-19-associated coagulopathy, supporting the concept of thromboinflammation. 5 

Correspondence

COVID-19 and its implications for thrombosis and anticoagulation

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Lille ICU Haemostasis CO-VID-19 Group. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence

Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19

Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms

The authors thank Inés Colmegna (McGill University) for support and help in interpreting the data and Isabelle Lefèvre, Catherine Pedrosa, Audrey Carlo, and François Depasse (Stago BioCare) for providing the QPlus cartridges.

None.